Omalizumab improves efficacy of oral immunotherapy for multiple food allergies – National Institutes of Health (press release)
Medgadget (blog) |
Omalizumab improves efficacy of oral immunotherapy for multiple food allergies
National Institutes of Health (press release) Combining a 16-week initial course of the medication omalizumab with oral immunotherapy (OIT) greatly improves the efficacy of OIT for children with allergies to multiple foods, new clinical trial findings show. After 36 weeks, more than 80 percent of … New Hope for Kids With Multiple Food Allergies The Growth of Allergy Immunotherapy Market ~10.85% CAGR | Focus on Top Key Players Profile | Forecasts to 2023 Allergy Immunotherapy Market : Segmental Highlights and Table of Content (2017 – 2025) |
